Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0835 or +27 21 938 0967
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR201402000719423 Date of Registration: 03/12/2013
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant
Official scientific title Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial
Brief summary describing the background and objectives of the trial The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite P.falciparum and in healthy African adults exposed to the parasite. The safety and the tolerability of the vaccine will be assessed on the rate of solicited and unsolicited events/reactions. The safety profile will include local and systemic reactions/events as well as the biological safety, based on a clinically significant change of the baseline value of the main biological criteria.
Type of trial RCT
Acronym (If the trial has an acronym then please provide) AMA1 DiCo
Disease(s) or condition(s) being studied Infections and Infestations
Sub-Disease(s) or condition(s) being studied Malaria
Purpose of the trial Prevention
Anticipated trial start date 06/01/2014
Actual trial start date 06/01/2014
Anticipated date of last follow up 05/07/2015
Actual Last follow-up date 05/07/2015
Anticipated target sample size (number of participants) 66
Actual target sample size (number of participants) 66
Recruitment status Completed
Publication URL
Secondary Ids Issuing authority/Trial register
130642A-61 ANSM
NCT02014727 ClinicalTrials.gov ID
C12-18 Sponsor
2013-001920-20 EudraCT Number
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Randomised Simple randomisation using a radomisation table created by a computer software program Central randomisation by e-CRF Masking/blinding used Care giver/Provider,Outcome Assessors,Participants
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group AMA1-DiCo + GLA-SE or Alhydrogel (African subjects) AMA1-DiCo: 50µg GLA-SE 2.5 µg GLA per dose or Alhydrogel 0.85 mg aluminium per dose Do, W4, W26 Intramuscular Vaccination 18
Control Group Placebo (African subjects) isotonic saline solution Do, W4, W26 Intramuscular Vaccination 18 Placebo
Experimental Group AMA1-DiCo + Alhydrogel (European subjects) AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Do, W4, W26 Intramuscular Vaccination 15
Experimental Group AMA1-DiCo+ GLA-SE ( European subjects) AMA1-DiCo: 50µg GLA-SE 2.5 µg GLA per dose Do, W4, W26 Intramuscular Vaccination schedule 15
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
1. Age > 20 and < 45 years healthy female and male 2. General good health based on history, physical and laboratory examination 3. Written informed consent obtained before any trial procedure 4. Available to participate in follow-up for the duration of trial. 5. For Female and male volunteers: practicing contraception before and up to four (4) weeks after the third vaccination. Additionnal Inclusion criteria for malaria non-exposed European volunteers : 6. Reachable by phone during the whole trial period 7. Volunteers should be affiliated to a social security regimen 1. Positive pregnancy test 2. Active breast feeding 3. Previously participated in any malaria vaccine trial 4. History of blood transfusion within the last 6 months 5. Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers. 6. Any clinically significant laboratory abnormalities on screened blood samples beyond the normal range, as defined at the clinical trial site. 7. Enrolment in any other clinical trial during the whole trial period 8. Intake of chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding the screening visit or during the trial period except topical steroid use including intranasal. 9. Any confirmed or suspected immunosuppressive or immunodeficiency condition during the whole trial period 10. Volunteers unable to be closely followed for social, geographic or psychological reasons. 11. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the trial. 12. History of anaphylaxis or Known severe hypersensitivity to any of the vaccine components (adjuvant or antigen or excipient). 13. Vaccination or gammaglobulin within 4 weeks prior and after each vaccination. If a vaccination is necessary during this period; the volunteer will be withdrawn from the study. 14. Positive HIV, HBV (Ag HBS) and HCV tests. Additional Exclusion Criteria for malaria non exposed European volunteers: 15. History of malaria or travel in malaria endemic areas within the past twenty-six weeks. 16. Positive serology for malaria antigen PfAMA-1 17. Intention to travel to malaria endemic countries during the trial period. 20 Year(s) 45 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 19/11/2013 CERS
Ethics Committee Address
Street address City Postal code Country
Ouagadougou Burkina Faso
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
No 19/11/2013 Comité institutionnel de bioéthique du CNRFP
Ethics Committee Address
Street address City Postal code Country
Ouagadougou Burkina Faso
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 18/06/2013 CPP Ile de France III
Ethics Committee Address
Street address City Postal code Country
89 rue d'Assas Paris 75006 France
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 18/06/2013 Comité institutionnel de bioéthique du CNRFP
Ethics Committee Address
Street address City Postal code Country
Ouagadougou Burkina Faso
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Number of Adverse events Up to four weeks after the third vaccination
Secondary Outcome The humoral and cellular responses 6 months after the last vaccination
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
CIC BT 505 de vaccinologie Cochin Pasteur Hôpital Cochin Bâtiment Lavoisier 27 rue du faubourg St Jacques Paris 75014 France
CNRFP 1487 avenue Kumda Yonré Ouagadougou 01 Burkina Faso
FUNDING SOURCES
Name of source Street address City Postal code Country
EVI Germany
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor INSERM 8 rue de la Croix jarry Paris 75013 France Commercial Sector/Industry
COLLABORATORS
Name Street address City Postal code Country
EVI ImNeuenheimer Feld 326 Heidelberg 69120 Germany
BPRC Lange Kleiweg 161 Rijswijk Zh 2288 GJ Netherlands
CIC COCHIN 27 rue du faubourg Saint Jacques Paris 75014 France
CNRFP 1487 Avenue Kumda Yonré Ouagadougou 01 Burkina Faso
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Sodiomon Sirima s.sirima.cnlp@fasonet.bf Tel : + 226 50 32 46 95/6 1487 Avenue Kumda Yonré
City Postal code Country Position/Affiliation
Ouagadougou 01 Burkina Faso
Role Name Email Phone Street address
Principal Investigator Odile LAUNAY odile.launay@cch.aphp.fr 0033 158412860 27 rue du faubourg saint jacques
City Postal code Country Position/Affiliation
Paris 75014 France
Role Name Email Phone Street address
Public Enquiries Sonia GUEGUEN sonia.guegen@inserm.fr +33 1.44.23.61.05 8 rue de la Croix Jarry
City Postal code Country Position/Affiliation
Paris 75013 France
Role Name Email Phone Street address
Scientific Enquiries Odile LAUNAY odile.launay@cch.aphp.fr +33 158412860
City Postal code Country Position/Affiliation
Paris 75014 France
Role Name Email Phone Street address
Scientific Enquiries Odile LAUNAY odile.launay@cch.aphp.fr +33 158412860 27 rue du faubourg saint jacques
City Postal code Country Position/Affiliation
Paris 75014 France
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
URL Results Available Results Summary Result Posting Date First Journal Publication Date
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information